Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit in New York City on December 12, 2024. Frank Gleeson, Co-founder and CEO, will participate in a fireside chat titled 'Polypharmacy in DMD and Neuromuscular Disease' at 9:50AM ET. The management team will also be available for one-on-one meetings with registered summit attendees.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), un'azienda biotecnologica impegnata nello sviluppo di terapie a piccole molecole per malattie muscolari, annuncia la propria partecipazione al Oppenheimer's Movers in Rare Disease Summit che si terrà a New York il 12 dicembre 2024. Frank Gleeson, co-fondatore e CEO, prenderà parte a una conversazione informale intitolata 'Polifarmacologia nella DMD e nelle malattie neuromuscolari' alle 9:50 ET. Il team di gestione sarà inoltre disponibile per incontri individuali con i partecipanti registrati al summit.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), una empresa biotecnológica enfocada en el desarrollo de terapias de pequeñas moléculas para enfermedades musculares, anuncia su participación en el Oppenheimer's Movers in Rare Disease Summit en la ciudad de Nueva York el 12 de diciembre de 2024. Frank Gleeson, cofundador y CEO, participará en una charla titulada 'Polifarmacia en la DMD y en enfermedades neuromusculares' a las 9:50 AM ET. El equipo de gestión también estará disponible para reuniones individuales con los asistentes registrados al summit.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF)는 근육 질환을 위한 소분자 치료제를 개발하는 데 주력하는 생명공학 회사로, 2024년 12월 12일 뉴욕에서 열리는 Oppenheimer's Movers in Rare Disease Summit에 참여한다고 발표했습니다. Frank Gleeson 공동 창립자이자 CEO는 오전 9시 50분 ET에 'DMD 및 신경근육질환의 다약물 요법'이라는 주제로 대담에 참여할 예정입니다. 경영진 팀은 또한 등록된 서밋 참석자와의 일대일 미팅을 위해 대기할 것입니다.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), une entreprise biopharmaceutique axée sur le développement de thérapies à petites molécules pour les maladies musculaires, annonce sa participation au Oppenheimer's Movers in Rare Disease Summit qui se déroulera à New York le 12 décembre 2024. Frank Gleeson, co-fondateur et CEO, participera à une discussion informelle intitulée 'Polypathologie dans la DMD et les maladies neuromusculaires' à 9h50 ET. L'équipe de direction sera également disponible pour des réunions individuelles avec les participants inscrits au sommet.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), ein Biotech-Unternehmen, das sich auf die Entwicklung von kleinmolekularen Therapeutika für Muskelerkrankungen konzentriert, gibt seine Teilnahme am Oppenheimer's Movers in Rare Disease Summit in New York City am 12. Dezember 2024 bekannt. Frank Gleeson, Mitbegründer und CEO, wird an einem informellen Gespräch mit dem Titel 'Polypharmazie bei DMD und neuromuskulären Erkrankungen' um 9:50 Uhr ET teilnehmen. Das Management-Team wird außerdem für Einzelgespräche mit registrierten Teilnehmern des Gipfels zur Verfügung stehen.
- None.
- None.
Oppenheimer’s Movers in Rare Disease Summit
Title: Polypharmacy in DMD and Neuromuscular Disease
Format: Fireside Chat
Date: December 12, 2024
Time: 9:50AM ET
Additionally, management will be available for one-on-one meetings with registered attendees at the summit.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate SAT-3247 is currently in clinical development as a potential disease-modifying treatment DMD. Additionally, Satellos is leveraging its breakthrough research in muscle stem cell polarity and proprietary discovery platform MyoReGenX™, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203768538/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091
Source: Satellos Bioscience Inc.
FAQ
When is Satellos Bioscience (MSCLF) presenting at the Oppenheimer Rare Disease Summit?
What is the topic of Satellos Bioscience's (MSCLF) presentation at the Oppenheimer Summit?
Will Satellos Bioscience (MSCLF) management be available for meetings at the Oppenheimer Summit?
What type of therapeutics is Satellos Bioscience (MSCLF) developing?
